Vanguard Group’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$12.7M Buy
9,251,609
+230,839
+3% +$305K ﹤0.01% 2847
2025
Q3
$11.2M Buy
9,020,770
+761,642
+9% +$908K ﹤0.01% 2924
2025
Q2
$9.33M Buy
8,259,128
+191,575
+2% +$255K ﹤0.01% 2941
2025
Q1
$11.8M Buy
8,067,553
+66,861
+0.8% +$126K ﹤0.01% 2756
2024
Q4
$17M Sell
8,000,692
-327,007
-4% -$806K ﹤0.01% 2660
2024
Q3
$23.3M Buy
8,327,699
+132,033
+2% +$352K ﹤0.01% 2518
2024
Q2
$19.1M Sell
8,195,666
-11,898
-0.1% -$35.1K ﹤0.01% 2598
2024
Q1
$36.7M Sell
8,207,564
-823,261
-9% -$3.44M ﹤0.01% 2300
2023
Q4
$29M Sell
9,030,825
-1,556,979
-15% -$4.42M ﹤0.01% 2428
2023
Q3
$33.6M Buy
10,587,804
+3,086,311
+41% +$13.5M ﹤0.01% 2319
2023
Q2
$37.3M Buy
7,501,493
+196,157
+3% +$1.06M ﹤0.01% 2320
2023
Q1
$36.1M Buy
7,305,336
+40,115
+0.6% +$257K ﹤0.01% 2324
2022
Q4
$45.7M Buy
7,265,221
+102,139
+1% +$946K ﹤0.01% 2224
2022
Q3
$77.4M Sell
7,163,082
-1,243,065
-15% -$16.9M ﹤0.01% 1950
2022
Q2
$95.8M Buy
8,406,147
+1,652,167
+24% +$14.7M ﹤0.01% 1850
2022
Q1
$61.5M Buy
6,753,980
+12,141
+0.2% +$126K ﹤0.01% 2203
2021
Q4
$101M Buy
6,741,839
+46,119
+0.7% +$814K ﹤0.01% 1981
2021
Q3
$172M Buy
6,695,720
+93,414
+1% +$2.22M ﹤0.01% 1692
2021
Q2
$172M Buy
6,602,306
+645,613
+11% +$18.4M ﹤0.01% 1709
2021
Q1
$210M Buy
5,956,693
+170,216
+3% +$5.74M 0.01% 1552
2020
Q4
$146M Buy
5,786,477
+129,274
+2% +$4.21M ﹤0.01% 1641
2020
Q3
$213M Sell
5,657,203
-224,111
-4% -$8.45M 0.01% 1240
2020
Q2
$252M Buy
5,881,314
+1,781,863
+43% +$64.4M 0.01% 1128
2020
Q1
$79.7M Buy
4,099,451
+151,158
+4% +$3.6M ﹤0.01% 1656
2019
Q4
$103M Buy
3,948,293
+523
+0% +$14.4K ﹤0.01% 1738
2019
Q3
$108M Buy
3,947,770
+504,590
+15% +$14.4M ﹤0.01% 1681
2019
Q2
$92.4M Buy
3,443,180
+1,343,459
+64% +$37.4M ﹤0.01% 1794
2019
Q1
$60.7M Buy
2,099,721
+53,392
+3% +$1.55M ﹤0.01% 1997
2018
Q4
$55.1M Buy
+2,046,329
New +$54.4M ﹤0.01% 1982

Other funds holding ALLO